%0 Journal Article
%T Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP).
%A Pallapothu MR
%A Quintana Mariñez MG
%A Chakkera M
%A Ravi N
%A Ramaraju R
%A Vats A
%A Nair AR
%A Bandhu AK
%A Koirala D
%A Mohammed L
%J Cureus
%V 15
%N 10
%D 2023 Oct
%M 38021691
暂无%R 10.7759/cureus.46696
%X In this literature review, we will evaluate the effectiveness of OnabotulinumtoxinA (Botox) and anti-calcitonin gene-related peptide (anti-CGRP) in the treatment of migraine headaches. Both therapies are frequently prescribed for managing and preventing migraines and have received Food and Drug Administration (FDA) approval. The mechanism of action, side effects, compliance, cost-effectiveness, and migraine treatment provided by these two medicines were compared in the analysis of several studies. Many studies found that as Botox was administered by a doctor every three months and had fewer side effects than anti-CGRP, which is self-administered every month, it was more compliant than anti-CGRP. After examining the data, Botox is believed to be the most effective therapy. Although both therapies are efficient, this article compares them to determine which is the best management strategy.